Genzyme, TKT In Close Race And Patent Contest For Fabry Orphan Treatment
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Recent "complete review" letters for Genzyme’s Fabrazyme (agalsidase beta) and Transkaryotic Therapies’ Replagal (agalsidase alfa) appear to continue the companies’ neck and neck race for approval.